Efficacy and safety of onabotulinumtoxin A injection in male patients with detrusor overactivity after stress urinary incontinence surgery
Por:
Mateu-Arrom, L, Gutierrez-Ruiz, C, Rubio, LS, Barea, VM, Redorta, JP, Errando-Smet, C
Publicada:
1 ene 2022
Ahead of Print:
1 ene 2022
Resumen:
Introduction and objective: The use of onabotulinumtoxin A (BoNT-A) injection in male patients with detrusor overactivity (DO) after stress urinary incontinence (SUI) surgery has been scarcely described. Our aim was to assess results of this treatment in this specific population.
Materials and methods: Retrospective analysis of men with previous SUI surgery who had been treated with a first injection of 100 U BoNT-A because of DO since 2010 in our department. Treatment response was assessed with the Treatment Benefit Scale: 1) greatly improved; 2) improved; 3) not changed; 4) worsened after treatment (Treatment Benefit Scale 1 or 2: treatment response). Complications were classified according to the Clavien-Dindo classification. Treatment continuation was considered present if, at the last visit, patients had received a BoNT-A injection within the preceding 12 months. Pre-and post-treatment urodynamic variables were compared.
Results: Eighteen patients were included, median age 71.1 (59.1-83.5) years. Twelve (66.7%) patients reported response to treatment. Two (11.1%) complications were detected: urinary retention requiring clean intermittent catheterization (Clavien-Dindo 2). No complications related to previous SUI surgery were detected. Fifteen (83.3%) patients had a follow-up > 12 months (median follow-up 57 [15-89] months) and all of them had discontinued treatment at the end of follow-up. Urodynamic studies showed significant improvement in terms of DO and bladder compliance.
Conclusion: Although most men with DO after SUI surgery respond to intradetrusor BoNT-A injection, all of them discontinue treatment due to personal reasons. It is a safe procedure, with urinary retention requiring clean intermittent catheterization being the most frequent complication. (C) 2021 AEU. Published by Elsevier Espana, S.L.U. All rights reserved.
Filiaciones:
Mateu-Arrom, L:
Fundacio Puigvert, Unidad Urol Func & Femenina, Barcelona, Spain
Gutierrez-Ruiz, C:
Fundacio Puigvert, Unidad Urol Func & Femenina, Barcelona, Spain
Rubio, LS:
Fundacio Puigvert, Unidad Urol Func & Femenina, Barcelona, Spain
Barea, VM:
Fundacio Puigvert, Unidad Urol Func & Femenina, Barcelona, Spain
Redorta, JP:
Fundacio Puigvert, Serv Urol, Barcelona, Spain
Errando-Smet, C:
Fundacio Puigvert, Unidad Urol Func & Femenina, Barcelona, Spain
|